MedTrace Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations

NCT07610798 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-05-28

No results posted yet for this study

Summary

This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.

Conditions

  • Advance Solid Tumors
  • Colon and Rectal Cancer
  • Non - Small Cell Lung Cancer NSCLC
  • Pancreatic Adenocarcinoma Advanced or Metastatic
  • Ovarian Cancer
  • Endometrial Cancer
  • Biliary Cancers

Interventions

DRUG

INV-8989

INV-8989 is admistered once weekly

Sponsors & Collaborators

  • Shenzhen Ionova Life Sciences Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07610798 on ClinicalTrials.gov